Journal article

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Tomas Radivoyevitch, Robert M Dean, Bronwen E Shaw, Ruta Brazauskas, Heather R Tecca, Remco J Molenaar, Minoo Battiwalla, Bipin N Savani, Mary ED Flowers, Kenneth R Cooke, Betty K Hamilton, Matt Kalaycio, Jaroslaw P Maciejewski, Ibrahim Ahmed, Görgün Akpek, Ashish Bajel, David Buchbinder, Jean-Yves Cahn, Anita D'Souza, Andrew Daly Show all

Leuk Res | Published : 2018


BACKGROUND: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). METHODS: 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. RESULTS: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL ..

View full abstract